Glaxo to form leading Japanese vaccine company with Daiichi Sankyo
Pharmaceuticals giant GlaxoSmithKline (GSK) expects to create the number one vaccines company in Japan after forming a joint venture (JV) with Japanese peer Daiichi Sankyo.
Pharmaceuticals giant GlaxoSmithKline (GSK) expects to create the number one vaccines company in Japan after forming a joint venture (JV) with Japanese peer Daiichi Sankyo.
The JV, in which each company owns an equal 50/50 stake, will supply globally recommended vaccines to help protect people of all ages in Japan, GSK said. These vaccines include the Human Papillomavirus (HPV) vaccine, the Rotavirus vaccine, the Seasonal flu vaccine, the Mumps vaccine, the Diphtheria Pertussis (DTP) vaccine, and the Measles Rubella (MR) vaccine.
Both GSK and Daiichi will sell their respective vaccines into the JV at agreed upon prices and expect sales synergies from the JV.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"This collaboration marks another step in our strategy to build our presence in key growth markets and will create the first and largestcompanydedicated solely to vaccinesin Japan," said President Designate of GSK Christophe Weber.
"We areverypleased to bepartneringwith Daiichi Sankyo, a highlyregardedcompanyand an established leader in Japan. Both companies have strong track records in commercialisation and, in combination, will create further significant economies of scale in the development and distribution of vaccines in the Japanese market," he said.
Both groups will investment a combined total of 100m yen (around £0.8m) to cover the start-up capital requirements of the JV.
BC
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Spot the Dog: £67bn in underperforming funds revealed
Around 137 funds consistently underperformed their benchmark, BestInvest's Spot the Dog report finds. Which funds are in the dog house?
By Katie Williams Published
-
What does a BP and Shell merger mean for the UK oil industry?
BP’s struggles have made it vulnerable to a takeover. Could it merge with Shell to create a British behemoth?
By Dr Matthew Partridge Published